Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 100 5r 2?
Displaying drugs 11176 - 11200 of 12939 in total
Amibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.
Investigational
Matched Iupac: … ethyl 2-{[(7S)-7-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydronaphthalen-2-yl]oxy …
Matched Salts cas: … 121524-09-2
ATN-161 is a non-RGD based integrin binding peptide targeting alpha-5 beta-1 and alpha-v beta-3. It inhibits the migration and adhesion of particular integrins on activated endothelial cells that play a critical role in tumor angiogenesis. This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective...
Investigational
Matched Iupac: … (2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-{[(2S)-1-acetylpyrrolidin-2-yl]formamido}-3-(1H-imidazol-5-yl)propanamido …
Matched Description: … ATN-161 is a non-RGD based integrin binding peptide targeting alpha-5 beta-1 and alpha-v beta-3. ... Since the expression of alpha(5)beta(1) integrin by cancer cells and the role of this molecule in tumor …
Experimental
Matched Iupac: … 2-(diethylamino)ethyl 3-(naphthalen-1-yl)-2-[(oxolan-2-yl)methyl]propanoate …
Investigational
Matched Iupac: … (2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-5-[(diaminomethylidene)amino]-2-[2-(methylamino ... pentanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-3-(1H-imidazol-5- ... yl)propanoyl]pyrrolidin-2-yl]formamido}propanoic acid …
Experimental
Matched Iupac: … (2R,3S)-N'-hydroxy-N-[(1S)-1-(methylcarbamoyl)-2-phenylethyl]-2-(2-methylpropyl)-3-[(thiophen-2-ylsulfanyl …
Investigational
Matched Iupac: … (2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido ... ]pyrrolidin-2-yl]formamido}-3-(4-hydroxyphenyl)propanamido]-4-methylpentanoic acid ... ]-4-(methylsulfanyl)butanamido]-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanamido]propanoyl …
Experimental
Matched Iupac: … [(1R)-1-(naphthalen-1-yl)-2-(naphthalen-2-yl)-2-oxoethyl]phosphonic acid …
Experimental
Matched Iupac: … (2R)-N'-hydroxy-N-[(1S)-1-(methylcarbamoyl)-2-phenylethyl]-2-(2-methylpropyl)butanediamide …
Experimental
Matched Iupac: … 1-(2-{2-[bis(propan-2-yl)amino]ethoxy}phenyl)butan-1-one …
A sympathomimetic agent that was formerly used as an anorectic. It has properties similar to those of dextroamphetamine. It has been implicated in lipid storage disorders and pulmonary hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1223)
Illicit
Withdrawn
Matched Iupac: … 1-(4-chlorophenyl)-2-methylpropan-2-amine …
Experimental
Matched Iupac: … (2S)-2-amino-2-carboxyethan-1-aminium …
Iodohippuric acid is under investigation in clinical trial NCT02599844 (Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults).
Investigational
Matched Iupac: … 2-[(2-iodophenyl)formamido]acetic acid …
Experimental
Matched Iupac: … magnesium(2+) (2S)-2-aminobutanedioate hydrochloride …
Dimenoxadol is an opioid analgesic which produces typical opioid effects such as analgesia and sedation. It is structurally similar to methadone and is a benzilic acid derivative. In the United States it is classified as a Schedule I controlled drug.
Experimental
Illicit
Matched Iupac: … 2-(dimethylamino)ethyl 2-ethoxy-2,2-diphenylacetate …
Experimental
Matched Iupac: … 2-{[2-(trifluoromethyl)phenyl]amino}benzoic acid …
Experimental
Matched Iupac: … (2Z)-2-(methylamino)but-2-enoic acid …
Experimental
Matched Iupac: … 2-[(2-methylpropyl)amino]ethyl 3-aminobenzoate …
Experimental
Matched Iupac: … 2-(dimethylamino)ethyl 2-(4-chlorophenoxy)acetate …
Experimental
Matched Iupac: … (2S,3R)-N-hydroxy-2-(3-hydroxypropyl)-N'-[(3S)-1-(2-methoxyethyl)-2-oxoazepan-3-yl]-3-(2-methylpropyl …
Investigational
Matched Iupac: … 4-{6-[(E)-2-[(3-methylphenyl)methylidene]hydrazin-1-yl]-2-[2-(pyridin-2-yl)ethoxy]pyrimidin-4-yl}morpholine …
Neuren Pharmaceuticals was developing Glypromate (glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for the potential treatment of neurodegenerative diseases by IV infusion. In December 2008, the company discontinued further development of the drug after it failed to show an observable effect.
Investigational
Matched Iupac: … (2S)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}pentanedioic acid …
Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, and Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma.
Investigational
Matched Iupac: … platinum(2+) 1-[(1R,2R)-2-(aminomethyl)cyclobutyl]methanamine (2S)-2-oxidopropanoate …
Experimental
Matched Iupac: … ({1-[2-(2-chlorobenzoyl)-4-nitrophenyl]-1H-imidazol-2-yl}methyl)diethylamine …
Experimental
Matched Iupac: … 1-{2-[(2-chlorophenyl)(phenyl)methoxy]ethyl}-4-[(2-methylphenyl)methyl]piperazine …
Experimental
Matched Iupac: … 2-(dimethylamino)ethyl 2,2-diphenyl-2-(prop-2-yn-1-yloxy)acetate …
Displaying drugs 11176 - 11200 of 12939 in total